Literature DB >> 33216696

Selecting Patients with Favorable Risk, Grade Group 2 Prostate Cancer for Active Surveillance-Does Magnetic Resonance Imaging Have a Role?

T Stonier1,2, A L Tin3, D D Sjoberg3, G Jibara1, A J Vickers3, S Fine1, J Eastham1.   

Abstract

PURPOSE: The National Comprehensive Cancer Network® recommends that selected men with grade group 2 prostate cancer be considered for active surveillance. However, selecting which patients with grade group 2 disease can be safely managed by active surveillance remains controversial. The aim of this study was to evaluate the association of multiparametric magnetic resonance imaging with adverse pathology in the radical prostatectomy specimen of men with favorable risk grade group 2 prostate cancer, which could help select patients for active surveillance.
MATERIALS AND METHODS: We retrospectively analyzed a cohort of patients with favorable grade group 2 disease who underwent radical prostatectomy between 2010 and 2019. Preoperative multiparametric magnetic resonance imaging was scored as negative (no identifiable lesion), positive (identifiable lesion) or equivocal. We defined a multivariable logistic regression model with multiparametric magnetic resonance imaging score as the predictor and adverse pathology (up staging to T3a/b disease, upgrading to ≥grade group 3 or lymph node invasion) as the outcome, adjusting for preoperative prostate specific antigen, biopsy Gleason grade, clinical stage, and number of negative and positive prostate biopsy cores. Secondary outcomes of biochemical recurrence, grade group upgrading alone and the added value of incorporating multiparametric magnetic resonance imaging data into the nomogram were also investigated.
RESULTS: We identified 1,117 patients with favorable risk grade group 2 disease who underwent radical prostatectomy. Positive multiparametric magnetic resonance imaging was associated with higher rates of adverse pathology (OR 2.55, 95% CI 1.75-3.40, p <0.0001) and upgrading (OR 3.89, 95% CI 2.00-7.56, p <0.0001). However, as our study included only grade group 2 patients who underwent radical prostatectomy, our cohort may represent a higher risk group than grade group 2 patients as a whole. Adding multiparametric magnetic resonance imaging results to a standard prediction model led to higher net benefit on decision curve analysis. An identifiable lesion on multiparametric magnetic resonance imaging was associated with an increased risk of aggressive pathological features in the radical prostatectomy specimen of patients with favorable risk grade group 2 prostate cancer who were potential active surveillance candidates. This information could be used to inform biopsy strategy, counsel patients on treatment options and guide strategies for those on active surveillance.
CONCLUSIONS: Combining multiple magnetic resonance imaging modalities (multiparametric magnetic resonance imaging) provides a more accurate prediction of the risk presented by prostate cancer than current prediction methods. In this study, positive magnetic resonance imaging results approximately doubled the chances that a patient with favorable risk prostate cancer would be found to have adverse pathology when their prostate was removed. Thus, multiparametric magnetic resonance imaging could help select patients with favorable risk cancer who may be good candidates for active surveillance, and help guide biopsy and surveillance strategies for such patients.

Entities:  

Keywords:  magnetic resonance imaging; prognosis; prostatic neoplasms; watchful waiting

Mesh:

Year:  2020        PMID: 33216696      PMCID: PMC8164388          DOI: 10.1097/JU.0000000000001519

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  13 in total

1.  Active surveillance eligibility of MRI-positive patients with grade group 2 prostate cancer: a pathological study.

Authors:  Guillaume Ploussard; Jean-Baptiste Beauval; Marine Lesourd; Cécile Manceau; Christophe Almeras; Richard Aziza; Jean-Romain Gautier; Guillaume Loison; Daniel Portalez; Ambroise Salin; Christophe Tollon; Michel Soulié; Bernard Malavaud; Mathieu Roumiguié
Journal:  World J Urol       Date:  2019-10-14       Impact factor: 4.226

2.  Prostate Imaging Quality (PI-QUAL): A New Quality Control Scoring System for Multiparametric Magnetic Resonance Imaging of the Prostate from the PRECISION trial.

Authors:  Francesco Giganti; Clare Allen; Mark Emberton; Caroline M Moore; Veeru Kasivisvanathan
Journal:  Eur Urol Oncol       Date:  2020-07-06

3.  Comparison of Pathological and Oncologic Outcomes of Favorable Risk Gleason Score 3 + 4 and Low Risk Gleason Score 6 Prostate Cancer: Considerations for Active Surveillance.

Authors:  Derek J Gearman; Alessandro Morlacco; John C Cheville; Laureano J Rangel; R Jeffrey Karnes
Journal:  J Urol       Date:  2017-12-07       Impact factor: 7.450

4.  Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology.

Authors:  James L Mohler; Emmanuel S Antonarakis; Andrew J Armstrong; Anthony V D'Amico; Brian J Davis; Tanya Dorff; James A Eastham; Charles A Enke; Thomas A Farrington; Celestia S Higano; Eric Mark Horwitz; Michael Hurwitz; Joseph E Ippolito; Christopher J Kane; Michael R Kuettel; Joshua M Lang; Jesse McKenney; George Netto; David F Penson; Elizabeth R Plimack; Julio M Pow-Sang; Thomas J Pugh; Sylvia Richey; Mack Roach; Stan Rosenfeld; Edward Schaeffer; Ahmad Shabsigh; Eric J Small; Daniel E Spratt; Sandy Srinivas; Jonathan Tward; Dorothy A Shead; Deborah A Freedman-Cass
Journal:  J Natl Compr Canc Netw       Date:  2019-05-01       Impact factor: 11.908

5.  Adverse Disease Features in Gleason Score 3 + 4 "Favorable Intermediate-Risk" Prostate Cancer: Implications for Active Surveillance.

Authors:  Alessandro Morlacco; John C Cheville; Laureano J Rangel; Derek J Gearman; R Jeffrey Karnes
Journal:  Eur Urol       Date:  2016-08-27       Impact factor: 20.096

6.  PI-RADS Version 2 Category on 3 Tesla Multiparametric Prostate Magnetic Resonance Imaging Predicts Oncologic Outcomes in Gleason 3 + 4 Prostate Cancer on Biopsy.

Authors:  Izak Faiena; Amirali Salmasi; Neil Mendhiratta; Daniela Markovic; Preeti Ahuja; William Hsu; David A Elashoff; Steven S Raman; Robert E Reiter
Journal:  J Urol       Date:  2019-01       Impact factor: 7.450

7.  Active Surveillance for Intermediate Risk Prostate Cancer: Survival Outcomes in the Sunnybrook Experience.

Authors:  Hima Bindu Musunuru; Toshihiro Yamamoto; Laurence Klotz; Gabriella Ghanem; Alexandre Mamedov; Peraka Sethukavalan; Vibhuti Jethava; Suneil Jain; Liying Zhang; Danny Vesprini; Andrew Loblaw
Journal:  J Urol       Date:  2016-08-26       Impact factor: 7.450

8.  Adverse Pathologic Findings for Men Electing Immediate Radical Prostatectomy: Defining a Favorable Intermediate-Risk Group.

Authors:  Hiten D Patel; Jeffrey J Tosoian; H Ballentine Carter; Jonathan I Epstein
Journal:  JAMA Oncol       Date:  2018-01-01       Impact factor: 31.777

9.  Clinical Significance of Multiparametric Magnetic Resonance Imaging as a Preoperative Predictor of Oncologic Outcome in Very Low-Risk Prostate Cancer

Authors:  Doo Yong Chung; Min Seok Kim; Jong Soo Lee; Hyeok Jun Goh; Dong Hoon Koh; Won Sik Jang; Chang Hee Hong; Young Deuk Choi
Journal:  J Clin Med       Date:  2019-04-19       Impact factor: 4.241

10.  Five-year Outcomes of Magnetic Resonance Imaging-based Active Surveillance for Prostate Cancer: A Large Cohort Study.

Authors:  Vasilis Stavrinides; Francesco Giganti; Bruce Trock; Shonit Punwani; Clare Allen; Alex Kirkham; Alex Freeman; Aiman Haider; Rhys Ball; Neil McCartan; Hayley Whitaker; Clement Orczyk; Mark Emberton; Caroline M Moore
Journal:  Eur Urol       Date:  2020-04-30       Impact factor: 20.096

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.